iiinova — where your digital self keeps evolving

CLARITY_Initiative @clarityinitiative.bsky.social · 29/09/2026

📢 Our latest commentary, "Old Drugs, New Evidence: SNAP and the Randomized Case for Cefazolin in MSSA Bacteremia," is now available. Explore the evolving evidence and its implications for clinical practice. @gurujosh.bsky.social @steventong.bsky.social clarityinitiative.org/commentaries...

071

CLARITY_Initiative @clarityinitiative.bsky.social · 27/08/2026

#26th edition in Spanish and Mandarin of #ADVANCE-ID Bacterial & Fungal Infections Newsletter out now! clarityinitiative.org/spanish-vers... clarityinitiative.org/chinese-vers...

clarityinitiative.org

Clarity Initiative

Suscríbete al ADVANCE-ID Newsletter en español y mantente informado sobre las últimas investigaciones en salud.

010

CLARITY_Initiative @clarityinitiative.bsky.social · 19/08/2026

#27th edition of #ADVANCE-ID Bacterial & Fungal Infections Newsletter out now! clarityinitiative.org/english-vers...

clarityinitiative.org

#27 (English) ADVANCE-ID Bacterial & Fungal Infections Newsletter

Dear readers,

000

Reposted by CLARITY_Initiative

Angela Huttner @angelahuttner.bsky.social · 14/08/2026

Happy to be part of this free online series introducing the use of statistics within clinical trials, conceived and developed by the superstars of ADVANCE-ID #IDSky #MedSky #EpiSky

1135

Reposted by CLARITY_Initiative

Steven Tong @steventong.bsky.social · 16/08/2026

Come along. This will be a great course in an amazing location!

011

CLARITY_Initiative @clarityinitiative.bsky.social · 11/06/2026

#21 (English) ADVANCE-ID Bacterial & Fungal Infections Newsletter out now! clarityinitiative.org/english-vers...

clarityinitiative.org

#21 (English) ADVANCE-ID Bacterial & Fungal Infections Newsletter

Dear readers,

000

Reposted by CLARITY_Initiative

Steven Tong @steventong.bsky.social · 01/01/2026

The 3rd and 4th commentaries on recent ID trials are up on the CLARITY website (we aim to publish in depth reviews of important ID stuies). This time looking at the GAMECHANGER trial: clarityinitiative.org/commentaries... @erinmccreary.bsky.social with Ahmad Mourad @gurujosh.bsky.social #IDSky

clarityinitiative.org

How Do We Win? The GAME CHANGER Trial

Erin K. McCreary, PharmD (1), Ahmad Mourad, MD MHS (2, 3)

0146

Reposted by CLARITY_Initiative

Josh Davis @gurujosh.bsky.social · 05/02/2026

My top 10 ID papers for 2025. Full citations and descriptions available at clarityinitiative.org/hot-takes Also see/hear our Communicable podcast episode on this at communicable.transistor.fm/episodes/com... What were your top 10? Any thoughts about what I missed welcome! #IDSky #Top10papers

13210

Reposted by CLARITY_Initiative

Steven Tong @steventong.bsky.social · 14/05/2026

ESCMID 2026 highlights COBRA Trial – One day is enough Dutch RCT: 1 day of antibiotics after ERCP drainage for cholangitis was non‑inferior to 4–7 days. Bottom line: Antibiotic durations can safely be much shorter once source control is achieved. #IDSky clarityinitiative.org/escmid-2026-...

clarityinitiative.org

Clarity Initiative

Clinical Literature Appraisal and Research education in InfecTious diseases

13117

Reposted by CLARITY_Initiative

Steven Tong @steventong.bsky.social · 16/05/2026

ESCMID 2026 highlights Dalbavancin PK (DOTS‑PK) – Two doses may not be enough High protein binding and wide inter‑patient variability: 1/3 patients may be sub‑therapeutic by day 22 Bottom line: Consider monitoring levels or adding a third dose in complex infections clarityinitiative.org/home

clarityinitiative.org

Clarity Initiative

Clarity Initiative offers clinical literature appraisal and research education in infectious diseases, enhancing knowledge through courses and resources.

1122